Development times for neurodegenerative disease drugs are significantly longer, particularly for those that are ultimately approved. Additionally, the post-development regulatory review process is often extended. Failure rates are mainly due to the complexity of the brain and nervous system and lack of understanding of the underlining mechanisms that lead to brain disorders and neurodegeneration.
Consequently, neurodegenerative drug discovery and development programs have been subjected to significant cutbacks and eliminations over the last few decades, affecting the entire drug development pipeline from discovery through to clinical trials and regulatory approval.
The integration of AI has enhanced the understanding of mechanisms, accelerated novel target identification and fueled advances in drug discovery for neurodegenerative diseases and other CNS disorders. It has helped in generating compounds with unique properties such as improved specificity or bioavailability. Overall, AI holds immense promise for understanding, diagnosing and managing neurodegenerative diseases, ultimately improving patient outcomes.
Register for this webinar today to gain insights on how AI is playing a crucial role in advancing CNS research related to neurodegenerative clinical drug development.
Join experts from TFS HealthScience, Anne-Marie Nagy, PhD, Vice President, Head of Internal Medicine & Neuroscience; and Sara Doan, BSc, DC, Executive Director, Program Strategy, Internal Medicine & Neuroscience, for the live webinar on Wednesday, September 18, 2024, at 11am EDT (4pm BST/UK).
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
A 2nd Chance Monitoring partners with industry-leading technology vendors including SCRAM Systems, Sentinel Advantage and Reconnect to deliver a fully managed solution. This includes everything from installation to ongoing monitoring and detailed reporting, ensuring that agencies can rely on a seamless, hassle-free service.
By offering a comprehensive, all-in-one solution, A 2nd Chance Monitoring enables agencies to focus on their core mission—enhancing public safety and supporting defendants—while leaving the complexities of electronic monitoring to the experts. The pretrial phase is a critical period in the justice process, and effective monitoring can play a key role in judicial decision-making by providing clear evidence of defendant compliance.
The NAPSA Conference is a premier event promoting pretrial justice and public safety through evidence-based decision-making and practices. NAPSA’s mission centers on fostering rational pretrial processes informed by objective standards and evidence. Attendees will have the opportunity to engage with industry leaders, explore the latest trends in pretrial services and collaborate on advancing the field with dignity, respect, and professional integrity.
“The NAPSA Conference allow us to demonstrate how our services align with the needs of pretrial services professionals,” added Schmidt. “We look forward to engaging with conference attendees and showcasing how our solutions can contribute to a more efficient and effective justice system.”
ABOUT A 2nd Chance Monitoring: A 2nd Chance Monitoring is dedicated to providing top-tier electronic monitoring services across the United States. With a focus on exceptional customer service and cutting-edge technology, A 2nd Chance Monitoring offers comprehensive solutions that support community supervision and ensure public safety. For more information, visit a2ndchancemonitoring.com.
“Providing a safe, effective and long-lasting method for vascular access is a significant challenge in hemodialysis treatment for patients with kidney failure,” said Darshana Zaveri. “Conventional methods such as surgical arteriovenous fistulas (AVF), arteriovenous grafts, or central venous catheters have not adequately met this need. Venova Medical’s technology aims to overcome the limitations of these traditional approaches, offering a transformative solution for patients dependent on hemodialysis”.
“Despite decades of tremendous efforts from healthcare providers, the vast majority of patients starting dialysis do so with a central venous catheter, subjecting them to increased risk of morbidity and mortality and cost to the U.S. healthcare system as compared to the safer AVF procedure,” stated Erik van der Burg, CEO of Venova Medical. “We believe that the Velocity pAVF System will become the new standard of care and reduce the barriers preventing a majority of patients from starting dialysis with an AVF.”
About Venova Medical
Venova Medical, Inc. is a privately held company addressing the challenges associated with providing optimal vascular access for patients needing hemodialysis. The company has developed the Velocity System, a next generation percutaneous AVF technology designed to reduce the need for reinterventions to achieve fistula maturation and improve vascular access outcomes while reducing costs. The company is currently conducting the prospective, single center, single-arm VENOS-1 clinical trial (NCT05757726) which is evaluating the safety and feasibility of Velocity System in patients on hemodialysis who are candidates for arteriovenous fistulas.
This release contains forward-looking statements, which represent estimates and assumptions with respect to certain future events, which are subject to significant risks and uncertainties. Products discussed in this release are in the investigational stage and have not yet been approved, nor are they available, for sale in the U.S. or any other country.
MMA isn’t just a sport; it’s a way of life. It’s about grit, discipline, and pushing through your limits. Through this initiative, participants are not only learning critical life skills and fitness but also receiving mentorship that provides the support they need to break cycles and conquer personal battles.
Studies show that combining mentorship with MMA is a game-changer—boosting confidence, reducing destructive behaviors, and helping people set and crush their goals.
“As soon as we opened the doors, we filled the place. The transformations among the participants have been incredible,” says Eric Klein, Founder and CEO of CAN-DO.ORG. “This new center and the Fighting Chance program give people more than just a workout—they gain a sense of purpose and community.”
Meeting a Need That Can’t Wait
In Los Angeles, taxpayer resources and donations for community programs are often misspent or unaccounted for, leaving a critical gap in accessible, high-quality programs that deliver real results. For young people aging out of foster care, those battling addiction, and others facing tough odds, free or low-cost program options are even slimmer.
“This isn’t about fighting—this is martial arts. It’s a discipline that weeds out bullies,” says Chase Gibson, founder of Fighting Chance. “It’s about learning to control your emotions and pushing yourself to grow. It’s what saved me, and I wanted to pass that on.”
CAN-DO.ORG took the lead in creating the Fighting Chance center, gutting and rebuilding the space from scratch to establish an MMA gym and community hub located on Fairfax Avenue in Los Angeles. It is a raw testament to their commitment to LA’s youth and empowering local leaders to drive real, sustainable change. With the success and growth of the program, they are looking to expand to a larger facility to accommodate more students and courses.
“Seeing this dream come to life with CAN-DO has been incredible,” adds Gibson. “This center wouldn’t have happened any other way.”
This is the second community MMA fitness center launched by CAN-DO.ORG in the last five years. With two decades of experience as a “spark plug” igniting change, CAN-DO.ORG empowers local leaders like Gibson by providing the space and tools to make a real, lasting impact.
A Call to Action: Help Us Keep the Momentum Going
The CAN-DO.ORG and Fighting Chance partnership is just getting started. To keep this movement alive and growing, we’re calling on individuals, corporate sponsors, and philanthropists to step up and support. Every dollar matters, and every donation goes directly into the programs—not to overhead or salaries.
“Too many nonprofits talk a big game but never show the score,” says Klein. “With CAN-DO, every donation counts because every dollar goes straight into the project. No one is lining their pockets here. We’re about transparency and results. Our donors see where their money goes, from start to finish.”
With this partnership’s success, CAN-DO.ORG aims to work with more local leaders to develop and launch additional fitness centers and mentorship programs across the U.S. The time to invest in our future is now. Let’s make it happen.
To Donate:
Web: CAN-DO.ORG/DONATE
Venmo: @NoRedTape
PayPal Giving Fund: CAN-DO Compassion Into Action Network
About CAN-DO.ORG:
CAN-DO.ORG (Compassion into Action Network – Direct Outcome) is a 501(c)(3) non-profit organization that donors can count on to get the job done. From natural disasters to humanitarian crises, we provide critical aid to communities that need it most in a timely and transparent manner. We are not tied down by politics or bureaucracy, and we do not delay resources by getting caught up in red tape. Outside of disaster relief work, CAN-DO.ORG’s community revitalization projects focus on long-term, self-sustaining solutions that empower and support local communities and disadvantaged groups. No matter what the project entails, CAN-DO.ORG’s impact lies in our commitment to working together with the locals in the communities we serve. We’re guided by the principles of transparency, dignity, and respect. Through meticulous accountability measures, CAN-DO.ORG upholds the trust of our donors and beneficiaries, ensuring all resources are utilized effectively and ethically. For more than two decades, CAN-DO.ORG’s results-based approach has never strayed: 100% Accountability, ZERO Red Tape.
“We are thrilled to partner with SE Healthcare to bring their Burnout Prevention Program to our Healers. After piloting the program, the feedback was overwhelmingly positive, with many of our employees appreciating the flexibility and customizability of the tools. This partnership is a significant step forward in our commitment to support our healthcare professionals and ensure they have the resources they need to thrive both professionally and personally.”
The SE Healthcare Burnout Prevention Program offers a holistic, web-based platform designed to address both organizational and individual factors contributing to burnout. The program has demonstrated effectiveness in reducing burnout levels and promoting a healthier work environment, which is essential for maintaining high standards of patient care and operational efficiency.
Greg Coticchia, CEO of SE Healthcare, highlighted the importance of this partnership:
“The well-being of the Healers at Norman is crucial not only for their own health but also for the quality of patient care. Our partnership with Norman Regional Health System is a testament to our commitment to tackling burnout head-on. By providing tools and strategies that support employee wellness, we are helping to create a more sustainable and effective healthcare environment. We are excited to work with Norman Regional and support their vision of enhancing community health and well-being.”
SE Healthcare’s Burnout Prevention Program is backed by compelling metrics that underscore its impact:
35% Reduction in Highest Level of Burnout: The program has successfully reduced the most severe burnout levels among participants.
52% Reported Reduced Burnout: Over half of participants using the program have experienced a significant decrease in burnout symptoms.
86% Utilization Rate: A vast majority of program participants are actively using the provided strategies both at work and at home, showcasing the program’s practicality and effectiveness.
Reduction in Turnover: Participating hospitals have seen a noticeable decrease in turnover, translating to substantial cost savings and improved continuity of care.
Improved Patient Outcomes: Enhanced clinician well-being directly contributes to better patient care, as evidenced by higher patient satisfaction scores and fewer medical errors.
The SE Healthcare Enrichment Center, which boasts over 300 microlearning sessions, will be an integral part of this program. These contributions will enrich the resources available to medical professionals, providing valuable insights and practical strategies for managing stress and preventing burnout. Currently, the Enrichment Center includes 96 CME credits and 138 microlearning modules for physicians, and 88 contact hour credits and 93 microlearning modules for nurses.
SE Healthcare’s partnerships with organizations like the American Nurses Association and American Association of Family Practitioners have further expanded the program’s reach. In just one year, over 10,000 ANA members have engaged in the program, more than 22,000 CNE credits have been issued, and nearly 50,000 microlearning sessions have been completed.
SE Healthcare’s Burnout Prevention Platform
Patented Innovation in Burnout Reduction:
SE Healthcare’s cutting-edge burnout platform is powered by pending patents, designed to revolutionize how medical professionals manage stress and burnout. Its advanced methods analyze and reduce burnout by understanding each clinician’s baseline stress levels and delivering personalized, actionable data and targeted content to help them effectively manage their stress.
Tailored Insights for Individual Healthcare Professionals:
The platform goes beyond general stress management by offering tailored insights and resources directly to healthcare professionals. This personalized approach ensures each professional receives the support they need to maintain their well-being and perform at their best.
Comprehensive Data for Organizational Leadership:
SE Healthcare’s patented system also empowers organizational leaders with detailed group data at various levels, from unit-specific insights to organization-wide reports. These insights help leaders understand stress and burnout trends over time, allowing for proactive adjustments to strategies and resources.
Real-Time Monitoring and Adaptive Support:
With regular check-ins, the system continuously monitors clinicians’ stress levels, providing real-time data that evolves with their needs. This dynamic approach ensures that actionable data and content are always relevant, addressing current challenges and promoting long-term well-being.
About SE Healthcare: SE Healthcare is dedicated to empowering healthcare professionals through innovative tools and strategies aimed at enhancing well-being and fostering a positive work environment. Our solutions are designed to improve retention, wellness, and patient outcomes, addressing the root causes of burnout and the pressures of the healthcare environment. With a focus on evidence-based programs and continuous improvement, SE Healthcare is at the forefront of creating a healthier, more efficient healthcare system.
About Norman Regional Health System: Norman Regional Health System is a multi-campus system that serves the health and wellness needs of communities throughout south central Oklahoma. Operated by the Norman Regional Hospital Authority, NRHS is committed to providing exceptional healthcare services and improving the overall well-being of its regional communities.
ASD is a neurodevelopmental disorder that is characterized by impairment in verbal and non-verbal communication skills, difficulty with social interactions and restricted and/or repetitive patterns of behavior or interests.¹ A study evaluating the prevalence of ASD in eight-year-old children found that in the US one in 36 is estimated to have ASD.²
Nobias’ proprietary AI technology, the Nobias Workbench™, distills disease drivers and optimal points for therapeutic intervention from rich clinical and genetic datasets. Under the collaboration, MTPA and Nobias used the Nobias Workbench™ to obtain a deeper understanding of ASD. The goal was to identify biological insights that could potentially lead to the discovery of therapeutic targets for the treatment of ASD.
“Our collaboration with MTPA brought together their team’s expertise in neurobiology and early development with Nobias’ focus on pediatrics and ability to derive novel insights from unique access to proprietary datasets,” said Patrick Dougherty, CEO of Nobias Therapeutics. “It was an honor to work with MTPA to enhance understanding of ASD and potentially help bring new therapeutic discoveries to patients.”
About Mitsubishi Tanabe Pharma America, Inc. Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). It was established by MTPC to develop and advance our pipeline as well as commercialize approved pharmaceutical products in North America. For more information, please visit http://www.mt-pharma-america.com or follow us on X (formerly Twitter), Facebook and LinkedIn.
About Mitsubishi Tanabe Pharma Corporation Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan’s pharmaceutical industry. MCG has positioned health care as its strategic focus in its management policy, “Forging the future”. MTPC sets the MISSION of “Creating hope for all facing illness”. To that end, MTPC is working on the disease areas of central nervous system, immuno-inflammation, diabetes and kidney, and cancer. MTPC is focusing on “precision medicine” to provide drugs with high treatment satisfaction and additionally working to develop “around the pill solutions” to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis. For more information, go to https://www.mt-pharma.co.jp/e/.
About Nobias Therapeutics Nobias Therapeutics is a pediatrics-first biotechnology company with a focus on genetically-defined rare diseases. Guided by deep analysis of unique clinical and genetic datasets, Nobias is developing a pipeline of novel small molecule therapeutics with the potential to be life-changing treatments for children and adolescents facing a broad range of debilitating disorders. Nobias recently reported positive data from a Phase 2 clinical trial of NB-001, a treatment for the neuropsychiatric symptoms associated with 22q11.2 Deletion Syndrome. To learn more, please visit http://www.nobiastx.com and follow Nobias Therapeutics on LinkedIn.
² Maenner MJ, Warren Z, Williams AR, et al. Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2020. MMWR Surveill. 2023;72(No. SS-2):1–14. DOI: http://dx.doi.org/10.15585/mmwr.ss7202a1
Sleep Better Solution offers ProSomnus, a highly advanced oral appliance that eases the symptoms of obstructive sleep apnea. The device fits like a dental mouthguard, providing a smooth and comfortable fit. ProSomnus holds the lower jaw forward and opens the airway to prevent obstruction.
ProSomnus helps with obstructive sleep apnea symptoms and snoring. It improves airflow during sleep, assisting patients in resting without constant interruptions. The device may also improve morning headaches, irritability, and exhaustion, allowing the patient and their partner to sleep well. It provides these benefits without a bulky external device, making treatment portable and convenient.
Medical insurance may cover sleep apnea solutions. Sleep Better Solution works closely with insurers and offers flexible payment plans. and also participates in Medicare, allowing services to be accessible to more patients.
Dr. Steven Liao, one of New Jersey Monthly’s Top Dentists and a member of the International Academy of Sleep, is a highly skilled and experienced practitioner. He received his Doctor of Dental Medicine degree from the University of Medicine and Dentistry of New Jersey.
Dr. Liao is excited about introducing these new services, “Among my dental patients, I discovered a need for sleep apnea treatment. Many patients cannot or do not want to use CPAP machines and need a less invasive alternative. Offering the ProSomnus appliance allows these patients and their families to sleep better and protect their health.”
Services Offered
Sleep Apnea Risk Assessment: As part of the assessment, an intraoral scanner is used to take 3D digital impressions which are used to assist the doctor in designing an oral appliance.
ProSomnus Oral Appliance: This device fits seamlessly into a sleep routine without the hassle of a machine.
About Sleep Better Solution
Sleep Better Solution provides obstructive sleep apnea treatment in Lodi, NJ. Dr. Liao provides the ProSomnus oral appliance to relieve sleep issues. The practice is conveniently located at 147 Main Street, Suite #7 Lodi, NJ 07644, and may be contacted online at https://www.sleepbettersolutionnow.com, or by calling 862-208-2112.
ClinOne connects, informs and empowers sites with a single, integrated platform to improve consent management, increase site productivity, enhance trial awareness and the patient and caregiver experience – all underpinned with comprehensive data insight tools and standards-based interoperability.
The acquisition is the logical next step in a successful two-year strategic partnership between the companies to help a growing list of sponsors and CROs leverage a single, integrated solution built on a deep understanding of both the site and patient journey.
uMotif CEO Steve Rosenberg (LinkedIn) explained, “There are natural synergies between uMotif and ClinOne, and together, in addition to the most modern eCOA/ePRO solution on the market, we now offer our customers best-in-class consent management along with several additional tools to alleviate the site and patient burden.”
ClinOne CEO Andrea Valente, (LinkedIn) commented, “We’re excited to integrate our solutions including eConsent, site productivity and trial awareness for HCPs into uMotif’s platform. Together we offer a breadth of capabilities to customers, sites and participants focused on quality, speed and an effective, purposeful experience.” Valente joins uMotif’s senior leadership team as Chief Operating Officer, Site Operations.
About uMotif
Putting patients first is in uMotif’s DNA. The uMotif eCOA/ePRO platform delivers faster, quality clinical trials and real-world studies by putting patients at the core of research. Through cloud-hosting in the US, Europe and China, the GCP, 21 CFR Part 11 and GDPR-compliant platform supports any study or trial, from Clinical Phase I, II and III studies through to decentralized or virtual real-world studies. Find out how uMotif can improve your clinical research programs and real-world studies at www.umotif.com
About ClinOne
ClinOne connects, informs, and empowers participants, care partners and sites in clinical trials with a true single platform for trial awareness, consent management, and participant experience/retention – underpinned with comprehensive data insights tools and standards-based interoperability. Visit www.clinone.com
According to Dr. Kirpal, “The new website better showcases our areas of expertise. We are known for saving even severely damaged, decayed, or infected natural teeth. It is our passion and our honor to help patients to preserve their natural teeth.”
“By preserving our patients’ natural teeth, we help them save money on costly dental restorations in the future. Preserving the natural teeth also safeguards patients from an altered facial appearance due to deterioration of the jawbone. Saving natural teeth also contributes to better oral health, which correlates with better overall health,” he added.
A graduate of the University of Michigan where he earned his Doctorate of Dental Surgery, Dr. Kirpal pursued his endodontic specialty degree from the New York University College of Dentistry.
His passion for his profession is evidenced by his status as a Double-Board Certified Endodontist, a rare distinction in the field. Earning Board-Certification is optional, but requires a significant time commitment, educational commitment, and rigorous testing. Dr. Kirpal completed the board certification process in both Canada and the United States.
Coastal Virginia Endodontics provides comprehensive endodontic treatments and procedures for all ages, including:
Non-surgical root canal
Minimally invasive endodontic surgery
Endodontic retreatment
Pulpotomy
Pulpectomy
Treatment for traumatic dental injuries
Treatment for cracked teeth
Emergency endodontic treatment
About Coastal Virginia Endodontics
Helmed by Dr. Abhishek Kirpal, Diplomate of the American Board of Endodontics, Coastal Virginia Endodontics PLLC is an all-age endodontic practice located at 762 Independence Blvd., Suite 400, Virginia Beach, VA 23455. To learn more, visit https://www.coastalvirginiaendo.com or call 757-557-0600
The FSHD Society’s seventh annual Walk & Roll to Cure FSHD is mobilizing thousands of affected individuals, families, and allies across the U.S. and Canada. Since its inception in 2018, the Walk & Roll campaign has grown from just five events to 32 locations across North America, raising over $4.5 million to support crucial research and programs. The Walk & Roll plays an important part in raising awareness and funds to combat FSHD and provides support to those living with it.
“The power of the Walk & Roll to Cure FSHD is so much more than fundraising. It strengthens the community of people impacted by FSHD, empowering them to do something where they may have felt powerless before. The community feeling that is created is something you cannot put a price tag on.” says Beth Johnston, Chief Community Engagement Officer at the FSHD Society, whose family also lives with FSHD.
Back as the National Ambassador for the Walk & Roll is actor, producer, and writer, Max Adler, best known for his role in the hit series Glee. Adler has also appeared in recent films such as The Trial of the Chicago Seven and Good Bad Things, a new film starring an actor with FSHD, as well as television shows like NCIS and Criminal Minds.
Adler shared, “A perfect example of the power and love of the FSHD community coming together is this: Recently, I received a message through social media from someone I had never met. They desperately needed a new motorized wheelchair to get around and be the mother they were meant to be but were out of money and options. I immediately reached out to all of my FSHD contacts, and within 48 hours, that person had a brand-new piece of equipment on the way to their house. That is the magic and strength of the love, impact, community effort, and powerful resources that come together when the FSHD Society shines its big bright light on the world. I’m proud to be a part of that through my efforts in the Walk & Roll.”
While Walk & Roll events take place throughout September and October, September 21st marks National Walk & Roll Day, a day for communities across North America to unite in support of those affected by FSHD. A special podcast episode of FSHD Straight Talk will feature interviews with volunteer leaders and highlights from Walk & Roll events, showcasing the dedication and resilience of those involved.
Don’t wait on the sidelines. Join the movement to cure FSHD. Visit https://www.FSHDSociety.org/Walk-Roll today to register, donate, and be part of the effort that’s changing lives. Together, we are paving the way to a brighter future for everyone affected by FSHD.
About the FSHD Society The FSHD Society is the world’s largest research and patient advocacy organization dedicated to facioscapulohumeral muscular dystrophy (FSHD). The Society supports families affected by this disease through programs like BetterLife, which empowers patients with tools to track symptoms and connect with researchers, and FSHD Navigator, a service providing personalized assistance to help navigate the challenges of living with FSHD. For over 30 years, the Society has driven major advancements in research and treatment development, with the mission to end the pain, disability, and suffering of those living with FSHD. “As long as we are here, no patient need ever face this disease alone.”
